comparemela.com
Latest Breaking News On - Adagrasib plus cetuximab - Page 1 : comparemela.com
Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC
Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.
Texas
United-states
Houston
San-diego
California
American
Daiichi-sankyo
Bristol-meyers-squibb
Redx-pharma
Eli-lilly
Navire-pharma
Genentech-roche
vimarsana © 2020. All Rights Reserved.